FG Backs Nasarawa University Hospital’s Push to Develop Lassa Fever Vaccine.
The Federal Government has pledged support for the Federal University Teaching Hospital, Lafia, Nasarawa State, in its efforts to develop a vaccine against Lassa fever, as Nigeria continues to battle the deadly viral disease.
The proposed vaccine development initiative is expected to contribute to ongoing efforts to strengthen Nigeria’s response to Lassa fever through research, scientific innovation and improved disease prevention.
During an inspection visit to the Centre for Vaccine Research and Biotechnology at FUTH Lafia on Friday, November 20, 2026, Coordinating Minister of Health and Social Welfare, Professor Muhammad Ali Pate, assured researchers of the Federal Government’s continued backing.
Ali Pate said the government would facilitate partnerships with internationally experienced institutions to strengthen the centre’s research capacity, improve infrastructure and develop the expertise of Nigerian scientists.
He disclosed that the centre already had vaccine candidates at early stages of development, describing their prospects as promising. He also commended the Nasarawa State Government, the hospital’s management and collaborating researchers for establishing the facility.
The centre’s Director, Professor Mustapha Imam, said the research team was working towards developing locally produced vaccines against Lassa fever and dengue fever. He emphasised the need for adequate funding, specialised equipment, training and infrastructure to advance the research.
Lassa fever remains a major public health concern in Nigeria, with healthcare workers among those affected by the disease. Despite decades of research, no licensed vaccine is currently available for its prevention, making vaccine development an important priority for Nigeria and other affected West African countries.
The Federal Government’s commitment is expected to strengthen domestic scientific research and support efforts to reduce the country’s dependence on imported vaccines and pharmaceutical products.







